Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study.

IF 2.3 3区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Abdominal Radiology Pub Date : 2024-10-11 DOI:10.1007/s00261-024-04620-1

Hao-Yang Tan, Shuang-Quan Liu, Jiu-Ling Zheng, Hong-Ying Liu, Yan-Han Liu, Guo-Hua Dai, Hua-Guo Feng

{"title":"Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study.","authors":"Hao-Yang Tan, Shuang-Quan Liu, Jiu-Ling Zheng, Hong-Ying Liu, Yan-Han Liu, Guo-Hua Dai, Hua-Guo Feng","doi":"10.1007/s00261-024-04620-1","DOIUrl":null,"url":null,"abstract":"Purpose: This retrospective study was conducted to evaluate the effectiveness and safety of a new combination therapy of radiotherapy (RT), hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) for hepatocellular carcinoma (HCC) patients involving portal vein tumor thrombus (PVTT).Methods: A total of 71 HCC patients with PVTT were retrospectively analyzed: 45 patients were treated by 'HAIC + TKI + ICI' therapy and 26 patients by the new combination therapy. The primary outcomes were overall survival (OS), progression-free survival (PFS), and cumulative survival rate.Results: The PFS in the 'New combination therapy' group was longer than that in the 'HAIC + TKI + ICI' group (HR 0.459, 95%CI 0.253-0.832; P = 0.008). Meanwhile, the OS in the 'New combination therapy' group was also longer than that in the 'HAIC + TKI + ICI' group (HR 0.420, 95%CI 0.198-0.894; P = 0.024). Compared with 'HAIC + TKI + ICI' group patients, the 'New combination therapy' group patients had higher 1-year PFS rate and 1-year OS rate (P = 0.029; P = 0.015). There was no significant difference in the incidence of adverse events between the two groups.Conclusion: The new combination therapy was an effective and safe non-surgical treatment for HCC patients with PVTT and could be considered a preferred therapy option.","PeriodicalId":7126,"journal":{"name":"Abdominal Radiology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Abdominal Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00261-024-04620-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This retrospective study was conducted to evaluate the effectiveness and safety of a new combination therapy of radiotherapy (RT), hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) for hepatocellular carcinoma (HCC) patients involving portal vein tumor thrombus (PVTT).

Methods: A total of 71 HCC patients with PVTT were retrospectively analyzed: 45 patients were treated by 'HAIC + TKI + ICI' therapy and 26 patients by the new combination therapy. The primary outcomes were overall survival (OS), progression-free survival (PFS), and cumulative survival rate.

Results: The PFS in the 'New combination therapy' group was longer than that in the 'HAIC + TKI + ICI' group (HR 0.459, 95%CI 0.253-0.832; P = 0.008). Meanwhile, the OS in the 'New combination therapy' group was also longer than that in the 'HAIC + TKI + ICI' group (HR 0.420, 95%CI 0.198-0.894; P = 0.024). Compared with 'HAIC + TKI + ICI' group patients, the 'New combination therapy' group patients had higher 1-year PFS rate and 1-year OS rate (P = 0.029; P = 0.015). There was no significant difference in the incidence of adverse events between the two groups.

Conclusion: The new combination therapy was an effective and safe non-surgical treatment for HCC patients with PVTT and could be considered a preferred therapy option.

查看原文本刊更多论文

肝动脉灌注化疗、TKI 和 ICI 联合放疗治疗伴门静脉瘤栓的肝细胞癌的疗效：一项回顾性队列研究。

目的：这项回顾性研究旨在评估放射治疗（RT）、肝动脉灌注化疗（HAIC）、酪氨酸激酶抑制剂（TKI）和免疫检查点抑制剂（ICI）联合治疗涉及门静脉肿瘤血栓（PVTT）的肝细胞癌（HCC）患者的有效性和安全性：回顾性分析了71名患有门静脉瘤栓的HCC患者：45名患者接受了 "HAIC+TKI+ICI "疗法，26名患者接受了新的联合疗法。主要结果为总生存期（OS）、无进展生存期（PFS）和累积生存率：结果："新联合疗法 "组的PFS长于 "HAIC + TKI + ICI "组（HR 0.459，95%CI 0.253-0.832；P = 0.008）。同时，"新联合疗法 "组的OS也长于 "HAIC + TKI + ICI "组（HR 0.420，95%CI 0.198-0.894；P = 0.024）。与 "HAIC + TKI + ICI "组患者相比，"新联合疗法 "组患者的1年PFS率和1年OS率更高（P = 0.029; P = 0.015）。两组患者的不良反应发生率无明显差异：结论：新的联合疗法是一种有效、安全的非手术治疗方法，可用于治疗PVTT的HCC患者，可作为首选治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Abdominal Radiology Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

5.20

自引率

8.30%

发文量

334

期刊介绍： Abdominal Radiology seeks to meet the professional needs of the abdominal radiologist by publishing clinically pertinent original, review and practice related articles on the gastrointestinal and genitourinary tracts and abdominal interventional and radiologic procedures. Case reports are generally not accepted unless they are the first report of a new disease or condition, or part of a special solicited section. Reasons to Publish Your Article in Abdominal Radiology: · Official journal of the Society of Abdominal Radiology (SAR) · Published in Cooperation with: European Society of Gastrointestinal and Abdominal Radiology (ESGAR) European Society of Urogenital Radiology (ESUR) Asian Society of Abdominal Radiology (ASAR) · Efficient handling and Expeditious review · Author feedback is provided in a mentoring style · Global readership · Readers can earn CME credits